上海药明生物技术有限公司 Wuxi Biologics
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Embrace Change to Turn Challenges into Opportunities: WuXi Biologics Successfully Hosted the 2nd Investor Day 2020-06-19 17:56
WuXi Biologics (Suzhou) Received EMA GMP Certificate for Biosafety Testing 2020-06-16 08:00
WuXi Biologics Signs Lease for a Clinical Manufacturing Facility in the United States 2020-06-09 08:00
WuXi Biologics Sweeps 2020 CMO Leadership Awards in All Six Categories 2020-05-28 08:00
WuXi Biologics Closes Land Deal to Build State-of-the-Art Biologics Production Facility in the United States 2020-05-19 08:00
WuXi Biologics and Aravive Form Strategic Collaboration to Develop Novel High-Affinity Bispecific Antibodies Targeting Cancer and Fibrosis Using the WuXiBody™ Platform 2020-04-30 19:00
WuXi Biologics Successfully Completes PFS Filling at its Robotic Aseptic Filling Facility 2020-04-28 08:00
WuXi Biologics Completed Acquisition of a Drug Product Manufacturing Facility in Germany 2020-04-22 08:00
WuXi Biologics (Suzhou) Successfully Passed First EMA GMP Inspection 2020-04-14 08:00
WuXi Biologics Achieved Remarkable Results in 2019 2020-03-26 21:32
WuXi Biologics Completes Weather-Tight Seal of its Biologics Manufacturing Facility in Ireland 2020-03-11 08:00
WuXi Biologics and Vir Biotechnology Announce Collaboration for Global Development of Antibodies to Treat COVID-19 2020-02-25 21:30
WuXi Biologics Congratulates Immutep on Positive Interim Data for IMP-321 2020-02-24 08:00
WuXi Biologics' Subsidiary WuXi Vaccines Signed Long-Term Vaccine Manufacturing Contract with a Global Vaccine Leader 2020-02-18 18:42
WuXi Vaccines Signed Long-Term Vaccine Manufacturing Contract with a Global Vaccine Leader 2020-02-18 18:18
WuXi Biologics Provides Back-to-work Operation Update Related to the Coronavirus Outbreak 2020-02-12 08:00
WuXi Biologics Provides Operation Update Related to the Coronavirus Outbreak 2020-01-29 10:44
WuXi Biologics Enables Development of Multiple Neutralizing Antibodies for Novel Coronavirus 2020-01-29 10:00
WuXi Biologics and Bayer Enter into an Acquisition Agreement on a Drug Product Plant in Germany 2020-01-16 10:39
WuXi Biologics and Almirall Sign Strategic Collaboration Agreement for Multiple Bispecific Antibodies Targeting Dermatology Diseases 2020-01-09 17:10
1 3 4 5 6 7 9